CN Patent

CN121263418A — 大环ras抑制剂

Assigned to Ruixin Pharmaceutical Co · Expires 2026-01-02 · 0y expired

What this patent protects

本公开的特征在于能够抑制Ras蛋白的式(la)或(lb)的大环化合物及其药物组合物和蛋白质复合物，以及它们在治疗癌症中的用途。

USPTO Abstract

本公开的特征在于能够抑制Ras蛋白的式(la)或(lb)的大环化合物及其药物组合物和蛋白质复合物，以及它们在治疗癌症中的用途。

Drugs covered by this patent

Lumakras (SOTORASIB) · Amgen

Patent Metadata

Patent number: CN121263418A
Jurisdiction: CN
Classification: —
Expires: 2026-01-02
Drug substance claim: No
Drug product claim: No
Assignee: Ruixin Pharmaceutical Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.